ArticleIJID regions2026
Economic burden of chronic pulmonary aspergillosis in Uganda: a cost-of-illness analysis.
Article in IJID regions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Chronic pulmonary aspergillosis (CPA) is a complication of tuberculosis that is under-recorgnizedin resource-limited settings. We quantified the economic burden of CPA in Uganda from societal, healthcare system, and household perspectives. Methods: We used a prevalence-based cost-of-illness approach with an estimated 26,765 annual CPA cases, stratified by clinical subtype. Direct medical costs were obtained from local health facilities and Joint Medical Stores pricing. Undiagnosed cases were modeled through a tuberculosis misdiagnosis pathway with 20% annual mortality. Productivity losses were estimated using disability-adjusted life years (DALYs), valued at Uganda's gross domestic product (GDP) per capita ($1072.70). We used return-on-investment (ROI) analysis to compare full (100%) diagnostic coverage with the current estimated 10%. Structural scenario analyses varied undiagnosed mortality (15-30%), healthcare costs, and baseline coverage. Results: At 100% coverage, total annual direct medical costs were $20,136,000 and productivity losses were $63,642,000, giving a total economic burden of $83,778,000 (0.16% of GDP), with 1,833 deaths and 59,329 DALYs. At 10% coverage, the burden was $162,749,000 (0.30% of GDP). Expanding coverage from 10% to 100% generated net savings of $78,971,000 (ROI of 4.73:1), robust across all scenarios (range 2.50 - 8.99). Mean out-of-pocket expenditure was $256.47 per patient, representing a catastrophic burden for low-income households. Total burden was most sensitive to annual CPA cases, while mortality among undiagnosed patients most influenced net savings. Conclusion: CPA imposes a substantial economic burden in Uganda. Underdiagnosis leads to avoidable mortality, productivity losses, and catastrophic costs. Integrating CPA screening into tuberculosis services and expanding diagnostic capacity are justified strategies aligned with Uganda's universal health coverage goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.